{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:50:18Z","timestamp":1793915418703,"version":"4.8.0"},"reference-count":63,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Ovarian cancer is the fifth most common cancer among women, with an estimated 19,680 new cases projected in 2024. Adjuvant chemotherapy remains the standard treatment for epithelial ovarian cancers but is frequently associated with adverse events, such as chemotherapy-induced alopecia (CIA). CIA is a particularly distressing side effect that significantly affects the body image, self-esteem, and quality of life of patients. Unfortunately, CIA remains underexplored in patients with ovarian cancer. Methods: This scoping review analyzed PubMed- and EMBASE-indexed studies investigating the incidence, severity, and mechanisms of CIA in ovarian cancer patients. Eighteen studies were included for analysis. Results: Our analysis identified platinum-based compounds, taxanes, and topoisomerase I inhibitors as the agents most strongly correlated with severe alopecia, particularly in combination regimens such as carboplatin\u2013paclitaxel (CP), and cyclophosphamide, adriamycin, and cisplatin (CAP). Among the monotherapies, taxanes, including paclitaxel and docetaxel, posed the highest risk of CIA. Mild-to-moderate alopecia was observed in patients treated with gemcitabine or pegylated liposomal doxorubicin. Alternative factors such as dosing schedules and prior chemotherapy exposure also significantly influence CIA severity. Conclusions: Given the profound psychosocial impact of CIA, optimizing treatment protocols to reduce the severity of alopecia without compromising therapeutic efficacy is crucial. These findings offer insights that may guide future therapeutic strategies for improving patient outcomes and quality of life.<\/jats:p>","DOI":"10.3390\/cancers17030411","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T07:46:29Z","timestamp":1737963989000},"page":"411","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chemotherapy-Induced Alopecia in Ovarian Cancer: Incidence, Mechanisms, and Impact Across Treatment Regimens"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5173-0698","authenticated-orcid":false,"given":"Simonetta I.","family":"Gaumond","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela E.","family":"Beraja","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Kamholtz","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina M.","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami H.","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin J.","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1002\/cncr.11345","article-title":"Pathology and Classification of Ovarian Tumors","volume":"97","author":"Chen","year":"2003","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian Carcinomas: Five Distinct Diseases with Different Origins, Genetic Alterations, and Clinicopathological Features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Zuo, R., Li, X., Hu, J., Wang, W., Lu, B., Zhang, H., Cheng, X., Lu, W., Qin, J., and Liu, P. (2024). Prediction of Ovarian Cancer Prognosis Using Statistical Radiomic Features of Ultrasound Images. Phys. Med. Biol., 69.","DOI":"10.1088\/1361-6560\/ad4a02"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial Ovarian Cancer: Evolution of Management in the Era of Precision Medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhu, Q.C. (2022). A Review of Co-Registered Transvaginal Photoacoustic and Ultrasound Imaging for Ovarian Cancer Diagnosis. Curr. Opin. Biomed. Eng., 22.","DOI":"10.1016\/j.cobme.2022.100381"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/AOG.0000000000005211","article-title":"Executive Summary of the Ovarian Cancer Evidence Review Conference","volume":"142","author":"Burke","year":"2023","journal-title":"Obstet. Gynecol."},{"key":"ref_7","unstructured":"Arora, T., Mullangi, S., Vadakekut, E.S., and Lekkala, M.R. (2024). Epithelial Ovarian Cancer. StatPearls, StatPearls Publishing."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/GO.21.00085","article-title":"Assessment of Adult Women with Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline","volume":"7","author":"Vanderpuye","year":"2021","journal-title":"JCO Glob. Oncol."},{"key":"ref_9","unstructured":"American Cancer Society (2024, December 31). Ovarian Germ Cell Tumor Treatment|Ovarian Teratoma Treatment. Available online: https:\/\/www.cancer.org\/cancer\/types\/ovarian-cancer\/treating\/germ-cell-tumors.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The Side Effects of Platinum-Based Chemotherapy Drugs: A Review for Chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pon.1245","article-title":"Chemotherapy-Induced Alopecia and Effects on Quality of Life among Women with Breast Cancer: A Literature Review","volume":"17","author":"Lemieux","year":"2008","journal-title":"Psychooncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.3390\/curroncol30040275","article-title":"Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?","volume":"30","author":"Wikramanayake","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00520-023-07634-5","article-title":"Hair Loss during and after Breast Cancer Therapy","volume":"31","author":"Rose","year":"2023","journal-title":"Support. Care Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/jocd.12308","article-title":"Chemotherapy-Induced Alopecia Management: Clinical Experience and Practical Advice","volume":"16","author":"Rossi","year":"2017","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e11031","DOI":"10.15252\/emmm.201911031","article-title":"CDK4\/6 Inhibition Mitigates Stem Cell Damage in a Novel Model for Taxane-Induced Alopecia","volume":"11","author":"Purba","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1592\/phco.23.1.104.31918","article-title":"Recurring Chemotherapy-Associated Alopecia Areata: Case Report and Literature Review","volume":"23","author":"Motl","year":"2003","journal-title":"Pharmacotherapy"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.bmt.1703695","article-title":"Relationship between Irreversible Alopecia and Exposure to Cyclophosphamide, Thiotepa and Carboplatin (CTC) in High-Dose Chemotherapy","volume":"30","author":"Dalesio","year":"2002","journal-title":"Bone Marrow Transplant."},{"key":"ref_18","first-page":"5","article-title":"Chemotherapy-Induced Hair Loss","volume":"15","year":"2010","journal-title":"Skin Ther. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","article-title":"Pathobiology of Chemotherapy-Induced Hair Loss","volume":"14","author":"Paus","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00018-018-2954-1","article-title":"Comprehensive Review on How Platinum- and Taxane-Based Chemotherapy of Ovarian Cancer Affects Biology of Normal Cells","volume":"76","author":"Witucka","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"ref_21","unstructured":"Tinker, A. (2024, December 17). Protocol Summary for Therapy for Invasive Epithelial Ovarian Cancer Using Cisplatin. Available online: http:\/\/www.bccancer.bc.ca\/chemotherapy-protocols-site\/Documents\/Gynecology\/GOOVCIS_Protocol.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1525-1438.1992.02060301.x","article-title":"Novel, Dose Intensive, Single-Agent Cisplatin in the First-Line Management of Advanced Stage Ovarian Cancer","volume":"2","author":"Palmer","year":"1992","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"International Collaborative Ovarian Neoplasm Group (2002). Paclitaxel plus Carboplatin versus Standard Chemotherapy with Either Single-Agent Carboplatin or Cyclophosphamide, Doxorubicin, and Cisplatin in Women with Ovarian Cancer: The ICON3 Randomised Trial. Lancet, 360, 505\u2013515.","DOI":"10.1016\/S0140-6736(02)09738-6"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus Platinum-Based Chemotherapy versus Conventional Platinum-Based Chemotherapy in Women with Relapsed Ovarian Cancer: The ICON4\/AGO-OVAR-2.2 Trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus Carboplatin Compared with Carboplatin in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus Paclitaxel Once a Week versus Every 3 Weeks in Patients with Advanced Ovarian Cancer (MITO-7): A Randomised, Multicentre, Open-Label, Phase 3 Trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated Liposomal Doxorubicin and Carboplatin Compared with Paclitaxel and Carboplatin for Patients with Platinum-Sensitive Ovarian Cancer in Late Relapse","volume":"28","author":"Wagner","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_29","first-page":"CD006910","article-title":"Pegylated Liposomal Doxorubicin for Relapsed Epithelial Ovarian Cancer","volume":"2013","author":"Lawrie","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0959-8049(00)00400-7","article-title":"Paclitaxel, Cisplatin and Lonidamine in Advanced Ovarian Cancer. A Phase II Study","volume":"37","author":"Lorusso","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized Trial of Single Agent Paclitaxel given Weekly versus Every Three Weeks and with Peroral versus Intravenous Steroid Premedication to Patients with Ovarian Cancer Previously Treated with Platinum","volume":"41","author":"Rosenberg","year":"2002","journal-title":"Acta Oncol."},{"key":"ref_32","first-page":"2303","article-title":"Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer","volume":"24","author":"Liu","year":"2019","journal-title":"J. BUON"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1200\/JCO.1994.12.11.2301","article-title":"Phase II Trial of Docetaxel in Patients with Platinum-Refractory Advanced Ovarian Cancer","volume":"12","author":"Francis","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/ijgc-00009577-200211000-00003","article-title":"Docetaxel in Combination with Carboplatin for Chemo-Naive Patients with Epithelial Ovarian Cancer","volume":"12","author":"Aoki","year":"2002","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/annonc\/mdm136","article-title":"Docetaxel and Oxaliplatin in the Second-Line Treatment of Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II Study","volume":"18","author":"Ferrandina","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin versus Topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","article-title":"Sorafenib plus Topotecan versus Placebo plus Topotecan for Platinum-Resistant Ovarian Cancer (TRIAS): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"19","author":"Chekerov","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0090-8258(03)00413-X","article-title":"Gemcitabine Combined with Cisplatin as First-Line Treatment in Patients with Epithelial Ovarian Cancer: A Phase II Study","volume":"91","author":"Belpomme","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ygyno.2005.03.032","article-title":"A Multicenter Phase II Study of Gemcitabine, Paclitaxel, and Cisplatin in Chemona\u00efve Advanced Ovarian Cancer","volume":"98","author":"Gupta","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/sj.bjc.6604878","article-title":"Gemcitabine-Oxaliplatin Combination for Ovarian Cancer Resistant to Taxane-Platinum Treatment: A Phase II Study from the GINECO Group","volume":"100","author":"Weber","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13048-021-00790-4","article-title":"The Impact of Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer: An Updated Meta-Analysis of Randomized Clinical Trials","volume":"14","author":"Li","year":"2021","journal-title":"J. Ovarian Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/ajco.12074","article-title":"Oral Cyclophosphamide in Recurrent Ovarian Cancer","volume":"12","author":"Handolias","year":"2016","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_43","unstructured":"Awosika, A.O., Farrar, M.C., and Jacobs, T.F. (2024). Paclitaxel. StatPearls, StatPearls Publishing."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1002\/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J","article-title":"Paclitaxel-Induced Cell Death: Where the Cell Cycle and Apoptosis Come Together","volume":"88","author":"Wang","year":"2000","journal-title":"Cancer"},{"key":"ref_45","unstructured":"(2024, September 10). 254-Ovarian Recurrent PACLitaxel Three Weekly DISCONTINUED|eviQ. Available online: https:\/\/www.eviq.org.au\/medical-oncology\/gynaecological\/ovarian\/254-ovarian-recurrent-paclitaxel-three-weekly-disc."},{"key":"ref_46","first-page":"73","article-title":"Docetaxel in the Treatment of Ovarian Cancer","volume":"16","author":"Kavanagh","year":"2002","journal-title":"Oncology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/IGC.0b013e318234fa3a","article-title":"Phase II Study of Docetaxel Weekly in Combination with Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer","volume":"22","author":"Sorbe","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_48","first-page":"1038","article-title":"Phase I and Pharmacokinetic Study of ABI-007, a Cremophor-Free, Protein-Stabilized, Nanoparticle Formulation of Paclitaxel","volume":"8","author":"Ibrahim","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","article-title":"Increased Antitumor Activity, Intratumor Paclitaxel Concentrations, and Endothelial Cell Transport of Cremophor-Free, Albumin-Bound Paclitaxel, ABI-007, Compared with Cremophor-Based Paclitaxel","volume":"12","author":"Desai","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000011923","article-title":"Topotecan\u2014A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience","volume":"56","author":"Kollmannsberger","year":"1999","journal-title":"Oncology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","article-title":"Pharmacokinetics and Pharmacogenetics of Gemcitabine as a Mainstay in Adult and Pediatric Oncology: An EORTC-PAMM Perspective","volume":"78","author":"Ciccolini","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan Weekly Versus Conventional 5-Day Schedule in Patients with Platinum-Resistant Ovarian Cancer: A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2004.10.011","article-title":"A Phase II Study of Gemcitabine plus Carboplatin in Platinum-Sensitive, Recurrent Ovarian Carcinoma","volume":"96","author":"Kose","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III Trial of Gemcitabine Compared with Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_55","first-page":"229","article-title":"Pegylated Liposomal Doxorubicin in Ovarian Cancer","volume":"1","author":"Green","year":"2006","journal-title":"Int. J. Nanomed."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.2165\/00003495-200262140-00012","article-title":"Polyethylene Glycol-Liposomal Doxorubicin: A Review of Its Use in the Management of Solid and Haematological Malignancies and AIDS-Related Kaposi\u2019s Sarcoma","volume":"62","author":"Sharpe","year":"2002","journal-title":"Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","article-title":"Hair Disorders in Patients with Cancer","volume":"80","author":"Shapiro","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4103\/idoj.IDOJ_471_18","article-title":"A Descriptive Study to Analyze Chemotherapy-Induced Hair Loss and Its Psychosocial Impact in Adults: Our Experience from a Tertiary Care Hospital","volume":"10","author":"Saraswat","year":"2019","journal-title":"Indian. Dermatol. Online J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-Based Drugs for Cancer Therapy and Anti-Tumor Strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1200\/JCO.1998.16.10.3345","article-title":"Topotecan for the Treatment of Advanced Epithelial Ovarian Cancer: An Open-Label Phase II Study in Patients Treated after Prior Chemotherapy That Contained Cisplatin or Carboplatin and Paclitaxel","volume":"16","author":"Bookman","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lee, Y.-C., Lee, C.-H., Tsai, H.-P., An, H.-W., Lee, C.-M., Wu, J.-C., Chen, C.-S., Huang, S.-H., Hwang, J., and Cheng, K.-T. (2015). Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0132579"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1200\/JCO.2004.08.157","article-title":"Randomized Phase III Trial of Pegylated Liposomal Doxorubicin versus Vinorelbine or Mitomycin C plus Vinblastine in Women with Taxane-Refractory Advanced Breast Cancer","volume":"22","author":"Keller","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised Phase II Trial of Pegylated Liposomal Doxorubicin (DOXIL\/CAELYX) versus Doxorubicin in the Treatment of Advanced or Metastatic Soft Tissue Sarcoma: A Study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/411\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:37Z","timestamp":1759919797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030411"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030411","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]}}}